* Out of 153 patients, 20% needed a dose increase after 3 months, and this rose to 27% by 9 months, primarily by increasing injection frequency rather than dosage.
* Patients requiring updosing were typically those with more severe CSU symptoms and lower IgE levels, but side effects did not increase as a result of higher dosing.